XPC multifaceted roles beyond DNA damage repair : p53-dependent and p53-independent functions of XPC in cell fate decisions
Copyright © 2021 Elsevier B.V. All rights reserved..
Xeroderma pigmentosum group C protein (XPC) acts as a DNA damage recognition factor for bulky adducts and as an initiator of global genome nucleotide excision repair (GG-NER). Novel insights have shown that the role of XPC is not limited to NER, but is also implicated in DNA damage response (DDR), as well as in cell fate decisions upon stress. Moreover, XPC has a proteolytic role through its interaction with p53 and casp-2S. XPC is also able to determine cellular outcomes through its interaction with downstream proteins, such as p21, ARF, and p16. XPC interactions with effector proteins may drive cells to various fates such as apoptosis, senescence, or tumorigenesis. In this review, we explore XPC's involvement in different molecular pathways in the cell and suggest that XPC can be considered not only as a genomic caretaker and gatekeeper but also as a tumor suppressor and cellular-fate decision maker. These findings envisage that resistance to cell death, induced by DNA-damaging therapeutics, in highly prevalent P53-deficent tumors might be overcome through new therapeutic approaches that aim to activate XPC in these tumors. Moreover, this review encourages care providers to consider XPC status in cancer patients before chemotherapy in order to improve the chances of successful treatment and enhance patients' survival.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:789 |
|---|---|
| Enthalten in: |
Mutation research. Reviews in mutation research - 789(2022) vom: 04. Jan., Seite 108400 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zebian, Abir [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 14.06.2022 Date Revised 17.06.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.mrrev.2021.108400 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM342120654 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM342120654 | ||
| 003 | DE-627 | ||
| 005 | 20231226204825.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.mrrev.2021.108400 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1140.xml |
| 035 | |a (DE-627)NLM342120654 | ||
| 035 | |a (NLM)35690409 | ||
| 035 | |a (PII)S1383-5742(21)00037-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zebian, Abir |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a XPC multifaceted roles beyond DNA damage repair |b p53-dependent and p53-independent functions of XPC in cell fate decisions |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.06.2022 | ||
| 500 | |a Date Revised 17.06.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 Elsevier B.V. All rights reserved. | ||
| 520 | |a Xeroderma pigmentosum group C protein (XPC) acts as a DNA damage recognition factor for bulky adducts and as an initiator of global genome nucleotide excision repair (GG-NER). Novel insights have shown that the role of XPC is not limited to NER, but is also implicated in DNA damage response (DDR), as well as in cell fate decisions upon stress. Moreover, XPC has a proteolytic role through its interaction with p53 and casp-2S. XPC is also able to determine cellular outcomes through its interaction with downstream proteins, such as p21, ARF, and p16. XPC interactions with effector proteins may drive cells to various fates such as apoptosis, senescence, or tumorigenesis. In this review, we explore XPC's involvement in different molecular pathways in the cell and suggest that XPC can be considered not only as a genomic caretaker and gatekeeper but also as a tumor suppressor and cellular-fate decision maker. These findings envisage that resistance to cell death, induced by DNA-damaging therapeutics, in highly prevalent P53-deficent tumors might be overcome through new therapeutic approaches that aim to activate XPC in these tumors. Moreover, this review encourages care providers to consider XPC status in cancer patients before chemotherapy in order to improve the chances of successful treatment and enhance patients' survival | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Cell fate | |
| 650 | 4 | |a DNA damage response | |
| 650 | 4 | |a DNA repair | |
| 650 | 4 | |a Tumor suppressor | |
| 650 | 4 | |a XPC | |
| 650 | 4 | |a p53 | |
| 650 | 7 | |a DNA-Binding Proteins |2 NLM | |
| 650 | 7 | |a Tumor Suppressor Protein p53 |2 NLM | |
| 650 | 7 | |a XPC protein, human |2 NLM | |
| 650 | 7 | |a 156533-34-5 |2 NLM | |
| 650 | 7 | |a DNA |2 NLM | |
| 650 | 7 | |a 9007-49-2 |2 NLM | |
| 700 | 1 | |a El-Dor, Maya |e verfasserin |4 aut | |
| 700 | 1 | |a Shaito, Abdullah |e verfasserin |4 aut | |
| 700 | 1 | |a Mazurier, Frédéric |e verfasserin |4 aut | |
| 700 | 1 | |a Rezvani, Hamid Reza |e verfasserin |4 aut | |
| 700 | 1 | |a Zibara, Kazem |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Mutation research. Reviews in mutation research |d 2012 |g 789(2022) vom: 04. Jan., Seite 108400 |w (DE-627)NLM216126231 |x 1388-2139 |7 nnns |
| 773 | 1 | 8 | |g volume:789 |g year:2022 |g day:04 |g month:01 |g pages:108400 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.mrrev.2021.108400 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 789 |j 2022 |b 04 |c 01 |h 108400 | ||